
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen Inc. has demonstrated a solid operational performance with a trailing 12-month average selling price (ASP) for its tests increasing by 9.2% year-over-year, highlighting the effectiveness of its pricing strategy in a competitive diagnostics market. Additionally, the company has reported a notable revenue increase of 19% year-over-year over the first nine months of the year, driven by a combination of ASP growth and a 16% rise in volume, indicating robust demand for its testing products. Furthermore, Exagen's strategic plans to expand its sales territories and improvements in commercial leadership position the company favorably for sustained growth, supported by a healthy cash balance of $35.7 million as of the latest quarter.
Bears say
Exagen Inc. reported mixed results in its recent financial performance, with a revenue of $17.2 million but a GAAP EPS loss of -$0.21, which was below consensus expectations. The company has undergone significant cost-cutting measures, reducing its workforce by approximately 42 full-time equivalents, which raises concerns about its operational efficiency and sales capability moving forward. Additionally, while Exagen has a backlog of $3.5 million, the revenue recognition is expected to be inconsistent, contributing to a negative outlook on its financial stability and growth potential.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares